Eton Pharmaceuticals Inc (ETON) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eton Pharmaceuticals Inc   (NASDAQ: ETON)


Eton Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Eton Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Eton Pharmaceuticals Inc achieved a return on average assets (ROA) of 12.37 % in its second quarter of 2026 a new company high.

ROA has improved compared to -1.49% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 78 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2708, from total ROA ranking in the first quarter of 2026 at 3444.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 13.9 % 16.28 % 21.01 % 191.59 % 219.5 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 13 -1 -5 -7 -4
Return On Assets (TTM) 12.37 % -1.49 % -4.81 % -7.3 % -5.55 %
ETON's Total Ranking # 2708 # 3444 # 3169 # 3064 # 3238
Total Assets (TTM) in million 116 98 92 105 102
Seq. Total Assets Change 18.52 % 6.08 % -11.86 % 2.79 % 21 %
Seq. Net Income Change 645.05 % 4.79 % - - -

ETON's 5 Years Annual ROA >> Back to ETON Management Effectiveness >> Compare ETON ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 33
Sector # 79
Overall # 473

Return On Assets Statistics
High Average Low
12.37 %
-42.67 %
-160.95 %
(Jun 30 2026)   (Dec 31 2020)



  News about Eton Pharmaceuticals Inc Return on Assets ROA

Eton Pharmaceuticals Expands Portfolio Through Acquisition of Increlex, Reinforcing Commitment to Rare Disease Patients

In a significant move that underscores its commitment to patients with ultra-rare conditions, Eton Pharmaceuticals, Inc. has announced the acquisition of Increlex (mecasermin injection) from Ipsen. This strategic decision not only broadens Eton s product offerings but also aligns with its mission to develop and distribute medicines that can dramatically change lives.Increlex is a crucial treatment for children with severe primary insulin-like growth factor-1 deficiency (IGFD), a rare disorder that can lead to severe growth impairment and other health complications. The drug functions by mimicking the action of natural IGF-1, thereby promoting growth in eligible patients who cannot produce sufficient quantities of this essential hormone. The acquisition of Increlex provides Eton with the opportunity to enhance its focus on rare diseases, where unmet needs are often most pronounced and treatment options can be limited.



Financial Statements
Eton Pharmaceuticals Inc 's Assets $ 116 million ETON's Balance sheet
Eton Pharmaceuticals Inc 's Income $ 12 million Quarterly ETON's Income Statement
ETON's Income by Division See ETON's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 21.01 % 139.83 % 26.81 % -8.87 % 4.35 %
Total Assets in million 92 76 32 25 27
Y / Y Net Income Change - - - - -
Net Income in million -5 -4 -1 -9 -2
Annual Return On Assets -4.99 % -5.02 % -2.95 % -36.04 % -7.12 %

ETON's 5 Years Annual ROA >> Back to ETON Management Effectiveness >> Compare ETON ROA to its Competitors



More Return On Assets Ratios
ETON's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ETON's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ETON's Competitors
Subscribers only: Roa for Eton Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ETON's Customers

You may also want to know
ETON's Roi ETON's Inventory Turnover Ratio ETON's Growth Rates ETON's Dividend Comparisons
ETON's Profitability Ratios ETON's Asset Turnover Ratio ETON's Dividend Growth
ETON's Roe ETON's Valuation Ratios ETON's Financial Strength Ratios ETON's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %

Date modified: 2026-09-08T17:36:09+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.